Skip to main content

Table 2 PROGRESS clinical characteristics

From: The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes

Variable DrotAA
n = 882
Non-DrotAA
n = 11,610
Total
n = 12,492
P value
Medical/Surgical Status, n (%):     <0.001
   Medical 540 (61.2) 7232 (62.3) 7772 (62.2)  
   Surgical – Elective 127 (14.4) 1205 (10.4) 1332 (10.7)  
   Surgical – Emergency 215 (24.4) 3173 (27.3) 3388 (27.1)  
SIRS criteria met, n (%): (n = 858) (n = 11,241) (n = 12099) <0.001
   0 2 (0.2) 29 (0.3) 31 (0.3)  
   1 5 (0.6) 188 (1.7) 193 (1.6)  
   2 57 (6.6) 1198 (10.7) 1255 (10.4)  
   3 268 (31.2) 4063 (36.1) 4331 (35.8)  
   4 526 (61.3) 5763 (51.3) 6289 (52.0)  
Source of infection, n (%): (n = 856) (n = 11,260) (n = 12,116) <0.001
   Community acquired 529 (61.8) 6033 (53.6) 6562 (54.2)  
   Nosocomial – hospital acquired 217 (25.4) 3172 (28.2) 3389 (28.0)  
   Nosocomial – ICU acquired 110 (12.9) 2055 (18.3) 2165 (17.9)  
Type of infection, n (%): (n = 675) (n = 8380) (n = 9055)  
   Gram negative 392 (58.1) 4795 (57.2) 5187 (57.3) 0.67
  (n = 681) (n = 8396) (n = 9077)  
   Gram positive 371 (54.5) 3668 (43.7) 4039 (44.5) <0.001
  (n = 682) (n = 8678) (n = 9360)  
   Fungal 103 (15.1) 986 (11.4) 1089 (11.6) 0.003
Primary site of infection, n (%): (n = 861) (n = 11,301) (n = 12,162) 0.35
   Abdominopelvic 227 (26.4) 2642 (23.4) 2869 (23.6)  
   Bone or joint 13 (1.5) 160 (1.4) 173 (1.4)  
   Hematogenous 59 (6.9) 738 (6.5) 797 (6.6)  
   Indwelling catheter-dialysis access 3 (0.3) 79 (0.7) 82 (0.7)  
   Indwelling catheter-vascular access 11 (1.3) 163 (1.4) 174 (1.4)  
   Lung 366 (42.5) 5282 (46.7) 5648 (46.4)  
   Meninges 12 (1.4) 169 (1.5) 181 (1.5)  
   Skin or skin structure 44 (5.1) 586 (5.2) 630 (5.2)  
   Urinary tract 71 (8.2) 887 (7.8) 958 (7.9)  
   Other 55 (6.4) 595 (5.3) 650 (5.3)  
  1. DrotAA = drotrecogin alfa (activated); ICU = intensive care unit; PROGRESS = Promoting Global Research Excellence in Severe Sepsis; SIRS = Systemic Inflammatory Response Syndrome.